Newsletter | July 8, 2025
FEATURED EDITORIAL
Formulation Development Of A JAK1 Inhibitor Extended-Release Tablet
By Dileep Boinipally, Metsera
This scientific article presents a summary of the formulation development strategy of a JAK1 inhibitor extended-release tablet, with a focus on experimental design, data interpretation, and formulation decision-making.
MOST POPULAR NEWS
•
VIAVI Introduces Colocation Capability At VALOR Lab-As-A-Service Testing Facility
Seegene Launches STAgora, A New Platform For Infectious Disease Analytics
Adaptive Biotechnologies And Flatiron Health To Integrate clonoSEQ MRD Testing Into OncoEMR
SRHS Selects AccessDx Laboratory As Pharmacogenomics (PGx) Program Partner
Diatron Launches P780 Advanced Clinical Chemistry System
PathAI Receives FDA Clearance For AISight Dx Platform For Primary Diagnosis
STEMCELL Technologies Introduces STEMprep Tissue Dissociator System To Accelerate Research Discoveries
Tareen Dermatology Receives Accreditation From The College Of American Pathologists
Diasorin Submits LIAISON NES POC Molecular Diagnostics System And 4-Plex Respiratory Panel To FDA For 510(k) Clearance And CLIA Waiver
RetinalGenix Technologies Contracts With LabCorp To Support DNA/GPS Platform For Advanced Genetic And Retinal Health Screening
